Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Clin Pharmacol Ther. 2013 Jul 17;94(6):10.1038/clpt.2013.143. doi: 10.1038/clpt.2013.143

Figure 1.

Figure 1

Association between CYP2C9*2 and changes in (A) ALT and (B) AST levels in Caucasian PAH patients treated with bosentan. Data are presented as mean fold increase from baseline and were analyzed in a multivariate model corrected for body mass index (BMI); the P-value is indicated.